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Abstract
Voltage-gated sodium (Nav) channels represent an important class of drug target for 
pain and many other pathology conditions. Despite the recent advances in channelopa-
thies and structure-function studies, the discovery of Nav channel therapeutics is still 
facing a major challenge from the limitation of assay technologies. This chapter will focus 
on advancement and challenge of Nav drug discovery technologies including nonelec-
trophysiological assays, extracellular electrophysiological assays, and the newly evolved 
high-throughput automated patch clamp (APC) technologies.
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1. Introduction
Nav channels are among the most well-characterized drug targets for pain, epilepsy, cardiac 
arrhythmias, and neuromuscular diseases. Current Nav drugs were developed empirically, 
in most cases without knowing their precise molecular targets. Even though new clinical indi-
cations have been found for these early-generation Nav modulators, their lack of sufficient 
isoform selectivity significantly limits the therapeutic outcomes. For example, when lidocaine 
is used to treat neuropathic pain, it causes cardiac toxicity due to inhibition of Nav1.5 and 
causes sedation, convulsion, and cardiac arrhythmias due to inhibition of CNS Nav channels.
Subtype-selective modulation of Nav channels is essential for target drug development but 
extremely difficult to achieve due to high sequence homology in the Nav family. The prob-
lem is further confounded by the current screening assays. Several assay platforms, such 
as radioligand binding, ion flux, and fluorescence membrane potential assays, have existed 
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for several decades. They are cost-effective and amenable to high-throughput screening. 
However these assays have significant limitations. For instance, the ligand binding assays 
could not provide functional effects (e.g., agonism vs. antagonism). Ion flux and membrane 
potential assays only measure channel function indirectly and are prone to artifacts such 
as autofluorescence, ionophore, and cellular toxicity. Electrophysiology is considered as 
the gold standard. However, traditional electrophysiology is significantly limited by its low 
throughput and labor intense. In the past decade, the emergence of automated electrophysi-
ology has significantly increased the throughput, making it feasible to screen compounds 
using electrophysiology.
Same as any other drug targets, ion channel drug discovery refers to the process by which 
new candidate medications are discovered. This is a drug early development process lying 
between target validation biology research and drug clinic development. The process of ion 
channel drug discovery can be arbitrarily divided to three stages: primary screening, hit con-
firmation, and lead optimization (Figure 1). At the stage of primary screening, a large number 
(up to millions) of compounds are screened using various non- or indirect functional high-
throughput assay, such as radioligand binding, ion flux, or membrane potential assays. Often, 
a small set of tool compounds are used to validate the assay. After obtaining correlation to 
electrophysiology, the assay is chosen for ultra high-throughput screening (uHTS) develop-
ment and used for primary screening. Companion assays are also developed for counter 
screening to reduce assay artifacts or assess selectivity against other irrelevant targets. The 
uHTS assay performance is evaluated by assay stability, assay window, and hit rate, which 
is usually around 0.1% resulting in tens of thousands of potential hits. At the hit confirma-
tion stage, often automated patch clamp (APC) platforms are used to test HTS hits. Hits are 
conformed, and their selectivity is confirmed by counter screening against other relevant iso-
forms. At the lead optimization stage, compounds are optimized on multiple fronts, including 
potency, selectivity, DMPK properties, efficacy, and toxicity.
Figure 1. Ion channel drug discovery strategy. Strategies for the implementation of multiple assay platforms in Nav 
channel drug discovery in the three stages of drug early development: SAR, structure-action relation; MOA, mechanism 
of action; DMPK, drug metabolism and pharmacokinetics.
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2. Nonelectrophysiological technologies
Nonelectrophysiological assays include nonfunctional assays and indirect functional assays. 
Under nonfunctional assay category, there are radioligand binding, fluorescence polariza-
tion (FP), fluorescence resonance energy transfer (FRET), and a series of fragment-based lead 
discovery assays. These assays can detect high-affinity binding, which makes them useful 
for kinetic studies and lead optimization. However, their major limitation is that the ligand 
binding sometimes does not translate into functional effects.
Indirect functional assays include ion flux assay and fluorescence membrane potential assays. 
These assays do not have precise voltage control and do not directly measure channel con-
ductance. Hence, these assays are prone to false positives from autofluorescence, ionophore, 
off-target effect, and cellular toxicity and in many cases cannot detect state-dependent modu-
lators, thus needing to be redesigned [1] and validated using tool compounds in early assay 
development stage. Overall, these indirect functional assays have been commonly used for 
Nav channel drug discovery primary screening, due to their functional correlation and uHTS 
amenable assay properties.
2.1. Radioligand binding assays
Radioligand binding assays have been extensively employed for various targets. These assays 
are cost-efficient, amenable for automation, and relatively easy to perform. Due to the lack 
of functional information, this assay format is usually not used for primary screening, but 
often employed during lead optimization stage to determine binding affinity, kinetics, and 
mechanism of action.
Ligand binding assays address the affinity between a ligand and its target:  K = 1 /  K 
d
 , which can 
be measured from kinetic experiments. In association experiments, multiple  K 
obs
 are measured 
at different ligand concentrations [C]. And  K off is measured in dissociation experiment at equi-
librium condition. Then the association  K 
on
 and dissociation  K off rate constants can be calculated from Eq. 1, and  K 
d
 can be calculated from Eq. 2:
  K 
ob
  =  K off +  K on ×  [C] (1)
  K 
d
  =  K off  /  K on (2)
Binding experiments are relatively easy to perform and achieve high throughput. The assay 
development needs to avoid multiple issues, such as non-equilibrium dissociation and ligand 
depletions, which can be exacerbated by undetected impurities in the ligands studied.
Based on the nature of binding assays, the major limitation of this assay is that the studying 
subject compound needs to bind to the same or allosterically linked site of the ligand. This is 
particularly the case for Nav channels’ target, due to Nav channels’ high complexity and the 
high homology between intra-α subunit four domains and nine inter-Nav subtypes.
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2.2. Nonradioligand binding assays
Traditional nonradioligand binding assays use fluorescence labeling to detect binding, 
including fluorescence polarization (FP) to measure the change in the rotational speed of a 
fluorescent-labeled ligand once it is bound; total internal reflection fluorescence (TIRF) labels 
target instead of ligand to measure fluorescence rotational change upon ligand binding; fluo-
rescence resonance energy transfer (FRET) labels both ligand and target with a pair of donor 
and acceptor fluorescent molecules to measure fluorescent energy transfer. All these methods 
require that fluorescence labeling should not interfere with target-ligand interaction.
Another category of nonradioligand drug binding assays is fragment-based lead discov-
ery (FBLD) technologies. Among them, nuclear magnetic resonance (NMR) spectroscopy 
is considered as the gold standard, as it measures chemical shift between free and bound 
targets in 15N/1H, 13C/1H, and/or other labeled atom’s two-dimensional correlation spectra 
to provide molecular interaction information [2]. In the past decade, many label-free tech-
nologies emerged to provide new options (Table 1). Isothermal titration calorimetry (ITC) 
and microscale thermophoresis (MST) technologies measure thermodynamic change 
associated with ligand binding in solution. A quartz crystal microbalance (QCM) mea-
sures a mass variation per unit area via the change in frequency of a quartz crystal resona-
tor. Surface plasmon resonance (SPR), second harmonic generation (SHG), and biolayer 
interferometry (BLI) measure optical change through a sensor, which usually requires 
immobilizing one binding reaction component on the sensor surface. Typical applications 
of these FBLD technologies include fragment-based screening, binding studies for tar-
get engagement, Kd measurements, and protein conformational changes. Many of these 
methods, such as surface plasmon resonance (SPR), can provide insights to enzymatic 
reactions by directly monitoring and quantifying the binding and depletion of the reaction 
components in real time. The advancement of increased sensitivity and implementation 
of automated systems have broadened the use of FBLD technologies in drug discovery, 
especially in lead optimization drug discovery stage mechanism-of-action studies.
2.3. Membrane potential assays
Membrane potential assays have been widely used in Nav channel drug discovery. Two types 
of membrane potential assays have been developed [3, 4]. One uses membrane potential dye 
and fluorescence imaging plate reader (FLIPR) (Molecular Devices, Sunnyvale, CA). Another 
measures fluorescence resonance energy transfer (FRET) between a voltage-sensing oxonol 
acceptor and a fluorescent membrane-bound coumarin dye. Both methods have been used to 
identify modulators for Nav1.6, Nav1.7, and Nav1.8.
The major drawback for these assays is their reliance on using nonphysiological relevant toxin 
openers (e.g., veratridine, deltamethrin, or batrachotoxin) to elicit channel response. These 
toxins remove inactivation and causes persistent channel opening through its binding to the 
intracellular pore domain (Site 2). The assay can successfully detect inhibition by TTX and 
tetracaine, but it fails to detect Nav1.7-selective aryl sulfonamides, such as PF-05089771 and 
GX-936. A new strategy of eliminating key LA binding site mutation N1742 K in Nav1.7, 






















Kinetics No No Yes Yes Yes Yes Yes
Immobilization-
free
Yes Yes Yes No No No No
Label-free Optional Yes Optional Yes Yes No Yes
Throughput Medium Low Medium High Medium High Yes
Sensitivity High Medium Medium High High High Low
Mass 
dependent
No Yes Yes Yes Yes No Yes
Sample amount High High Low Low Low <1 ug Low
Costs High Low Medium Medium High High Medium
Vendor Multi NanoTemper, etc. Q-Sense, etc. Multi Biodesy ForteBio
Table 1. Fragment-based lead discovery (FBLD) technologies in drug discovery.
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combined with using a new activator 1KαPMTX, was recently reported [1]. This new assay 
was able to detect aryl sulfonamides, with significantly reduced sensitivity to LAs, hence 
shifting the assay toward non–pore-binding mechanism. Such a mechanism-specific assay 
design can be applied to other ion channels to facilitate discovering subtype-selective drug.
2.4. Ion flux assays
Early ion flux assays were primarily developed on radionuclide ions such as 45Ca2+ and 22Na+. 
However, in the 1980s the development of ion-selective fluorescent dye-based indicators rev-
olutionized the measurement of ion flux assay. This method provides an indirect functional 
detection for ion channel activity, especially for calcium and potassium channels due to the 
robust signals of calcium dye and thallium dye. Unfortunately, fluorescent Na+ dyes have rel-
atively weak signals and are not amenable to reporting Na+ concentration. However, Na+ con-
centration can be quantitated by using atomic absorption spectroscopy (AAS). Additionally, 
radioisotopic 22Na+ still can be used as a tracer for Nav flux assay [5].
3. Extracellular electrophysiological technologies
Extracellular electrophysiological recording technologies employ direct or indirect electrical 
stimuli to a population of cell, in most cases a whole well confluent cell, and record target 
ion channel activity either from direct electrical signal or indirect fluorescent dye methods. 
These methods provide electrophysiological-involved functional assays at extracellular level, 
which usually represent a more physiological relevant environment, thus different from 
non-electrophysiological assays and typical single-cell and subcell-level electrophysiological 
patch clamp assays.
3.1. Optogenetics assay
The integration of optogenetics tools with membrane potential assays provides a powerful 
approach for Nav channel research and drug discovery [6]. Instead of using nonphysiologi-
cal stimuli, optogenetics controls membrane potential by using light-activated channelrho-
dopsins (ChR2, ChR1, VChR1, and SFOs); therefore, channels can be populated to specific 
state, and state-dependent modulators can be identified. After optimizing the performance of 
channelrhodopsins and voltage reporters, this technique may contribute to Nav channel drug 
discovery. One potential drawback could be the introduction of false positives derived from 
interferences with channelrhodopsins and membrane potential dyes.
3.2. Electric field stimulation (EFS) assay
Recently, electric field stimulation (EFS) assay has been reported in studying Nav1.7 function 
in cultured rat sensory neurons. This method utilizes electrical field stimulation to evoke action 
potential and record action potential-driven calcium transients in the neurons through live cell 
imaging. This method provides a novel functional phenotypic assay platform to study voltage-
gated ion channels in the network of excitable primary cell and induced pluripotent stem cell [7].
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3.3. Multielectrode arrays (MEA)
Multielectrode arrays (MEAs) are a useful tool for monitoring the functional activity of sev-
eral individual, electrically excitable cells within a larger population. MEA platforms enable 
noninvasive, longitudinal monitoring of cellular networks over weeks and months, so activity 
patterns during development and functional effects of acute and chronic treatment paradigms 
could be determined [8–10]. Recently, the availability of multiwell MEA plates has allowed 
for increased throughput, offering the ability to perform complete concentration-effect curves 
on cell populations.
4. Classical electrophysiological technologies
Single-cell-based electrophysiology remains the gold standard assay for Nav channel research, 
since it controls membrane voltage and measures ionic current directly, therefore assessing 
channel activities at distinct states. Despite the high information content, the utility of manual 
patch clamp electrophysiology is significantly limited by high demand for labor and skills. 
Therefore, automated patch clamp (APC) platforms have emerged to meet this challenge.
4.1. APC development and advancement
Many automated patch clamp (APC) technology platforms have been developed in the past 
decade [11, 12]. These include lipid bilayer recording (e.g., Orbit, from Nanion Technologies), 
Xenopus oocytes’ two-electrode recording (e.g., OpusXpress, from Molecular Devices), glass 
pipette electrode recording (e.g., FlyScreen 8500, from Flyion), continuous microfluidic-based 
recording (e.g., IonFlux, Mercury, from Fluxion), and most notably chip- or plate-based pla-
nar recording technologies (Table 2, IonWorks HT, Quattro, PatchXpress 7000A, IonWorks 
Quattro, and Barracuda from Molecular Devices; QPatch16, QPatch HT, Qube from Sophion; 
Port-a-Patch, Patchliner SyncroPatch 96, 384PE, 768PE from Nanion). Among the planar plat-
forms, the third-generation IonWorks Barracuda, Qube, and SyncroPatch 384PE/768PE have 
gained the most attention due to their high throughput, i.e., recording 384 or more cells in 
parallel.
IonWorks Barracuda was launched in 2010 and was applied for compound screening on 
hERG, CaV2.2, and Nav channels [13–15]. Barracuda uses perforated-patch configuration; 
the seal resistance was ~120 MΩ for single-hole mode and ~35 MΩ for population patch mode 
(64 holes). In 2014, Qube (Biolin Scientific, Sweden) and SyncroPatch (Nanion Technologies, 
German) were introduced with promised giga-seal data quality. Both platforms use 384 chan-
nel digital amplifier and 384 pipetting robot, borosilicate glass-based single- or multi-hole 
chips, and programmable negative pressure to achieve whole-cell configuration. However, 
they also differ in many regards. For example, Qube adopts an in-chip microfluid design 
to enable solution exchange, while SyncroPatch uses a liquid handler (e.g., BiomeK) so the 
system can be integrated for automation. SyncroPatch also can integrate two 384 modules into 
one robot platform, so 768 well parallel recording is feasible.
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MDC/MDS Sophion Nanion Sophion Nanion
Throughput/run 1 1 1 32 384 48 16 384 768
Substrate material Glass Silicone 
rubber
Glass Silicone rubber Polyimide Silicon oxide Glass Glass Glass
Seal resistance, GΩ >1 >1 >1 ~0.1 ~0.2 >1 >1 >1 >1
Access resistance, MΩ <10 <10 <10 >10 15 <10 <10 <10 <10
Parallel recordings 1 96 1 64 384 48 16 384 384*2
Unique recording 1 16 1 32 384 48 8 384 768
Amplifier channels 1 96 1 32 384 48 8 384 384/768
Number of pipettes 1 or 2 1 N/A N/A 384 8 8 384 384
Solution switch time <10 ms 
(100%)
30 ms (100%) 100 ms 50 ms (100%) 50 ms 80 ms ≤20 ms 50 ms 50 ms
Compound washout Yes Yes Yes Yes No Yes Yes Yes Yes
Compound additions Yes Yes Yes Yes No No Yes Yes Yes
Unlimited compound 
additions
Yes Yes Yes Yes No No Yes Yes Yes
Internal perfusion Yes No Yes No No No Yes Yes Yes
Rs Cslow compensation Yes Yes Yes No No Yes Yes Yes Yes
In/out side out 
configuration
Yes No No No No No No No No
Single-cell recordings Yes Yes Yes Yes Yes Yes Yes Yes Yes
Population recordings No No No Yes 20/well Yes 64/well Yes 10/well No Yes 10/
well
Yes 8/4/well
Implement date 1976 2004 2009 2009 2014
Table 2. Automated patch system comparison.
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4.2. APC assay challenges
Even though the APC platform is superior to other nonfunctional or indirect functional assay 
methods by offering precise control of voltage-gated ion channels’ physiological condition 
and direct measurement of channel activity, this technology faces many challenges including 
throughput, success rate, stability, integrating high-throughput data analysis, and lowering 
the equipment and consumable costs. The recently launched third-generation APC systems 
are intended to meet these challenges as a “primary screener” to perform both robust high-
throughput screening and high-quality recording to support drug discovery and ion channel 
research. In order to bring out the best APC performance for each ion channel assay, there 
are many parameters that can be considered for optimization which will be discussed in the 
following section.
4.2.1. Cell line development and cell preparation
Since APC patches cell randomly from the cell suspension solution added into the system, 
the cell quality is critical for every APC assay. If it’s possible, researcher should always pur-
sue the best cell membrane electrophysiological property which includes homogeneous and 
high-target ion channel expression for good recording signal, high cell capacitance for easier 
cell catching, and good membrane property to facilitate achieving whole-cell configuration 
and stable recording. There are many methods that can be used to improve target expression 
such as choosing high expression host cell and expression system and test different medium 
and culture conditions. It is reported that using a gentle cell dissociation method followed 
by a thorough cell debris-removing protocol and adjusting cell solution density will improve 
APC success rate [16]. Also keeping the cell in serum-free medium and at lower temperature 
may improve current [17]. In cell line development and preparation optimization, it is vital to 
validate the target channel response by characterizing its electrophysiological and pharmaco-
logical properties by using reference compounds.
4.2.2. APC cell catching and forming whole-cell protocol
Two important parameters have to be optimized for APC recording, which are cell catching 
and breaking in pressure protocols and intracellular and extracellular solution compositions. 
Many APC systems allow programming advanced pressure protocol including holding, 
ramping, and rupturing steps to achieve best whole-cell configuration success rate. And some 
target and cell may be more sensitive to intracellular cesium and extracellular calcium ion con-
centrations, which usually help to achieve giga-seal. Since each target and cell line is different, 
one optimized pressure and solution protocol may not work well for other targets and cells.
4.2.3. Drug applications
Different APC systems utilize either vail (in lower-throughput platform) or plate (in higher-
throughput platform) format source to deliver compound mostly by using automated liquid 
handler. Compound application usually is executed after recording signal reaching stable. 
Based on the APC system compound adding and washing capability and recording stability, 
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researchers chose to apply multiple concentrations of a compound to one recording, which 
usually decrease recording success rate but increase throughput comparing to single-dose 
application per recording. Also in order to avoid compound sticking to its container or pipette, 
the siliconizing reagent for glass and other surfaces can be included in the compound buffer 
after being validated using reference compounds.
4.2.4. Recording stability
In order to validate the pharmaceutical effect from adding compound, it’s important to 
include positive and negative controls to monitor recording stability. In the ideal condition, 
the negative control recording should remain stable throughout the whole experiment, which 
requires cell membrane seal resistance, cell capacitance, and series resistance to remain stable. 
To achieve this, each APC assay usually needs to be optimized with various conditions, 
including intracellular and extracellular solution compositions, voltage protocol, pressure 
protocol, and experimental procedure design. Many times, the current decrease independent 
of any compound application can be observed, which is called “rundown.” For Nav channel, 
rundown is usually caused by the holding membrane voltage (Vm), in which the closer Vm to 
half inactivation, the stronger slow inactivation-inducing effect will occur. So in order to exam 
inactive state-dependent modulator, the Nav assay voltage protocol has to be well designed 
and validated.
4.2.5. High-throughput data analysis
High-throughput data analysis is another major challenge in developing APC assay, espe-
cially in performing high-throughput screening. It is essential to build a robust high-through-
put data analysis method in the assay development stage. To achieve this, two issues need to 
be overcome. One is data reduction strategy, which means extracting key parameters from 
each current sweep, such as peak current amplitude for signal change analysis, and three 
recording quality control (QC) parameters including seal resistance, cell capacitance, and 
series resistance. Another issue is to develop a robust and reliable data QC strategy to exclude 
poor-quality recordings, which can be achieved by using self-developed script program or 
commercial available software by setting proper QC criteria for the three QC parameters’ 
value and stabilities at the desired time points of the experiment.
5. Concluding remarks
The advancement of technologies has made significant impact on Nav channel research and 
drug discovery in the past decade. As true for all drug screenings, no universal screening 
strategy can fit for all needs. Currently, primary uHTS is usually performed by using a vali-
dated non-electrophysiological functional assay and followed up by APC assay for potential 
hits’ confirmation and characterization. Overall, the advancement of high-throughput APC 
coupled with rational assay designs has offered unprecedented capacity for Nav channel 
drug discovery.
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